Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001945503 | SCV002195363 | uncertain significance | Inherited glutathione synthetase deficiency | 2022-08-31 | criteria provided, single submitter | clinical testing | This sequence change replaces valine, which is neutral and non-polar, with methionine, which is neutral and non-polar, at codon 440 of the GSS protein (p.Val440Met). This variant is present in population databases (rs371147790, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with GSS-related conditions. ClinVar contains an entry for this variant (Variation ID: 1415236). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV003167177 | SCV003876676 | uncertain significance | Inborn genetic diseases | 2023-02-01 | criteria provided, single submitter | clinical testing | The c.1318G>A (p.V440M) alteration is located in exon 13 (coding exon 12) of the GSS gene. This alteration results from a G to A substitution at nucleotide position 1318, causing the valine (V) at amino acid position 440 to be replaced by a methionine (M). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
ARUP Laboratories, |
RCV003738113 | SCV004563699 | uncertain significance | not provided | 2023-11-29 | criteria provided, single submitter | clinical testing |